Condition: Hidradenitis Suppurativa · Sponsor: Incyte Corporation
The purpose of this study is to evaluate the maximal use of ruxolitinib cream in adult and adolescent participants with hidradenitis suppurativa.
This description comes directly from the study's public registry record.
Incyte Corporation Call Center (US) · 1.855.463.3463 · medinfo@incyte.com
Incyte Corporation Call Center (ex-US) · +800 00027423 · eumedinfo@incyte.com
Always discuss trial participation with your own doctor first.
| Saguaro Dermatology | Phoenix, Arizona, United States | Recruiting |
| First Oc Dermatology | Fountain Valley, California, United States | Completed |
| Amicis Research Center Valencia | Northridge, California, United States | Recruiting |
| Children'S Hospital of Orange County | Orange, California, United States | Recruiting |
| Clinical Trials Research Institute | Thousand Oaks, California, United States | Recruiting |
| Clarity Dermatology | Castle Rock, Colorado, United States | Recruiting |
| International Clinical Research Tennessee Llc | Sanford, Florida, United States | Recruiting |
| Lenus Research Medical Group, Llc | Sweetwater, Florida, United States | Recruiting |
| Trueblue Clinical Research | Tampa, Florida, United States | Recruiting |
| Lane Dermatology and Dermatologic Surgery | Columbus, Georgia, United States | Recruiting |
| Options Research Group, Llc | West Lafayette, Indiana, United States | Recruiting |
| Equity Medical, Llc | Bowling Green, Kentucky, United States | Recruiting |
+ 9 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07049575